Palliative Treatment of Advanced Lung Cancer with Radiotherapy and Thai Herbal Medicine as Supportive Remedy, Analysis of Survival
Keywords:
advanced lung cancer, palliative radiotherapy, Thai herbal medicineAbstract
Objective: To evaluate the outcome of Thai herbal medicine, Vilac Plus (G716/45) on standard palliative radiotherapy for advanced non small cell lung cancer, stage IIIB-IV compared with historic control from the literature reports.
Patients and Methods: Between March 2003-June 2006, thirteen patients of advanced non small cell lung cancer, stage IIIB -IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac PlusG716/45) as supportive remedy. This study was performed at Radiotherapy Division, Department of Radiology, Faculty of Medicine, KhonKaen University, KhonKaen 40002, Thailand. The results were analysed in the aspect of clinical benefit rate of survived patients more than 15 months, median survival time and overall survival rates. The survival curve was estimated by the Kaplan-Meier method.
Results: Thirteen patients (8 male, 5 female) of advanced non small cell lung cancer with poor performance status (Eastern Co-operative Oncology Group 2-3), stage IIIB 11 cases, stage IV 2 cases were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45) as supportive remedy. Median age was 66 years (range 44.4 -83 years). The pathological reports were classified to be squamous cell carcinoma (5 cases), adenocarcinoma (2 cases), bronchioalveolar carcinoma (1 case), mixed squamous and adenocarcinoma (1 case). There were 30.77% (4/13 cases) of clinically advanced lung cancer by evidenced of computed tomography chest scan / chest X-ray. The clinical benefit rate of survived patients more than 15 months was 84.62%. The median survival time was 28 months (range14-74 months).The overall 1, 2, 3, 4 and 5 survival year rates were 100%, 53.85%. 30.77%, 23. 08% and 15.38% respectively.
Conclusion: This pilot study was limitation in the aspect of a small number of patients, but all cases were in advanced stages of diseases with poor performance status. The results of this study were promising in the aspect of improving overall survival rates and cost effectiveness. The treatment of cancer patients has many interrelated and confounding factors that have to be sorted out so further research will be necessary.
Downloads
Metrics
References
Bonfill X. Lung cancer. In: Text book of evidence-based oncology. Williams C, ed. London: BMJ publishing Books 2003:203-23 2.
Whelen S, Smith TJ. Lung cancer. In: Handbook of advanced cancer care. Fisch M, Bruera E, eds. UK: Cambridge university press 2003:137-49.
Srisam-ang K.Podhipak A, Narksawat K. et al. Survival of patients with advanced non-small-cell lung cancer at Ubon ratchathani cancer center, Thailand. Southeast Asean J Trop Med Public Health,2005:36(4):994-1006.
M. Lyikesici, P. Yumuk. F. Dane, et al. Outcome of patients with stage Ill and IV non-small cell lung cancer in Marmara university Hospital, Istanbul, Turkey. Lung Cancer official Scientific Publication of the international association for the study of lung cancer. Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona. Spain 2005:49(2):5249.
R Huber. M. Schmidt. A Borgmeier, et al. Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer. Lung Cancer official Scientific Publication of the international association for the study of lung cancer, Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005: 49(2):S248.
S. Hasturk, N. hatabay. F Ece. et al. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer official Scientific Publication of the international association for the study of lung cancer. Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005: 49(2):S247.
M. Zimmermann, F. Luthi, A. Zouhair, et al. Gefitinib (Iressa) as first- line therapy in advanced non-small lung cancer. Lung cancer official scientific publication of the international association for the study of lung cancer Abstracts of the 11th World Conference on Lung Cancer 3-6 July 2005. Barcelona, Spain 2005:49(2):S276.
Wake B, Taylor R, Sandercock J. Hyperfractionated/accelerated radiotherapy regimens for the treatment of nonsmall cell lung cancer. A systematic review of clinical and cost-effectiveness. West Midlands Health Technology Assessment Collaboration (WMHTAC); 2002 (DPHE Report No.35): 65.
Search date 2001: primary sources Medline, Embase, it. Cochrane Library, reference lists. contact with experts in the field and Internet searches. Hansen O, Paarup H. Sorensen P. et al. Curative radiotherapy of local advanced non-small-cell lung cancer. Eight years of experience from Odense. Ugeskr Laeger 2005 Sep 12:167(37):3497-502
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. In: The Cochrane Library. Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd. Search date 1991; Primary sources Medline: Canceriit: hand searches of meetings abstracts. bibliographies of books, and specialist journals; consultation of trials registers of National Cancer Institute: UK Coordinating Committee for Cancer Research: the Union Internationale Contre le Cancer: and discussion with trialists.
Saunders M. Dische S., Barrett A, et al. Continuous. hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999: 52:137-48.
Sause W. Kolesar P, Taylor S. et al. Final results of phase Ill trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000:117:358-64.
Jeremic B, Shibamoto Y, Acimov L. et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995:13:452-8.
Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable nonsmall cell lung cancer : final report of an Australian multicentre trial. Radiother Oncol 1999:52:129-36.
Kawahara M. Kubota K. Furuse K. [Radiotherapy and chemotherapy for locally advanced non-small-cell lung cancer: report of a clinical trial and review of the literature. South Osaka Lung Cancer Chemotherapy Study Group]. Nihon Kyobu Shikkan Gakkai Zasshi 1993;31 Suppl:212-7.
Mirimanoff RO. Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. Lung Cancer 1994; 11 Suppl 3:S79-99.
Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005:128:3975-84.
Zwitter M. Comments on treatment strategy for locally advanced non-small cell lung cancer. Lung Cancer 2002: 38 Suppl 3:S33-5.
Chen JC, Bongard F. Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990: 160:207-11.
Emami B, Munzenrider JE, Lee DJ. Rene JB. Radical radiation therapy of advanced lung cancer: evaluation of prognostic factors and results of continuous and split course treatment. Cancer 1979:44:446-56.
Maddox AM, Valdivieso M, Lukeman J. Smith TL. Barkley HE, Samuels ML, et al. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and_ survival. Cancer 1983:52:2165-72.
Simone CB 2nd, Simone NL, Simone V. Simone CB Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1.Altern Ther Health Med 2007: 13(1):22-8.
Moss RW. Do antioxidants interfere with radiation therapy for cancer. Integr Cancer Ther 2007:6(3):281-92.
Suntorntanasat T, Banchonglikitkul C. Kiungsupaya P. et al. Acute oral toxicity test Herbal tonic solution (G716/ 45) Thailand Institute of Scientific and Technological Research. (Written personal communications) September 2003:1-8.
Amadi Pirasahid P, Suntorntanasat T. Analytical report on Herbal tonic solution (G716/45) Thailand Institute of Scientific and Technological Research. (Written personal communications) July 2004;1-3.
Durand Phillippe.Prost Michel. In Vitro study of Vilac Plus analysis. Kirial International laboratories Spiral, (Written personal communications) 3 rue des Mardors 21560 COUTERNON, France (Written personal communications). July 2006:1-4.
Lee S-S, Wei Y-H. Chen C-F, et al. Anti-tumor effects of polysaccharides of Ganoderma lucidum. Proc Int Symposium Ganoderma Sci. Auckland, 27-29 April, 2001; 1-6
Murakami A, Jiwajinda S, Koshimizu k, et al. Screening for in vitro anti-tumor promoting activities of edible plant from Thailand.Cancer Letters 1995:95:139-14.
Pesee M. Prathnadi P.Kirdporn S, et al. Palliative treatment of late stages of cancer with radiotherapy and Thai herbal medicine as supportive remedy (primary report of 4 cases). The asean journal of radiology Bangkok, Thailand 2003;9(3):195-208.
Pesee M. Prathnadi P.Kirdporn S. et al. Palliative treatment of advanced lung cancer with radiotherapy and Thai herbal medicine as supportive remedy. The asean journal of radiology. Bangkok. Thailand 2006:12(3) 149-76.
Greene FL. Compton CC, Fritz AG. et al, eds. AUCC Cancer staging Atlas. Springer. New York 2006. 167-76.
Kim HW.Kim BK. Biomedicinal triterpenoids of Ganoderma lucidum (Aphyllophoromycetideae). Int J of Med Mushroom 1999:1:121-38.
Van der Hem LG. Ling Zhi-8. Studies of a new immuno modulating agent. Trasplantation 1995:60:438-43.
Wang SY. Anti-tumor effect of Ganoderma Lucidum is mediated by cytokines released from activated macrophages and T-lymphocytes. Int J Cancer 1997;70: 699-705.
Murakami A, Kondo A. Nakamura Y. et al. Possible antitumor Promoting and identification of Active Constituent Cardomoin of Boesenbergia Pandurata. Biosci Biotech Biochem 1993;57(11):1971-3.
Cherng JM. Shieh DE, Chiang W. et al. Chemopreventive effects of minor dietary constitutents in common foods on human cancer cells. Bioscience, Biotechnology and Biochemistry 2007:71(6):1500-4.
Morita N, Hayashi K, Fujita A. et al. Extraction of antiviral substances from Houttuynia cordata Thunb. Chemical abstract 1995:123:93249j.
Hayashi K, Kamiya M. Hayashi T. Virucidal effects of the steam distillate from Houttuynia cordata and its components on HSV-1, influenza virus and HIV. Plant Med 1995: 61(3):237-41.
Kim Y, Chongviriyaphan N, Liu C. Russell RM. Wang XD. Combined antioxidant (beta-carotene, alpha-tocopherol and ascorbic acid) supplementation increases the levels of lung retinoic acid and inhibits the activation of mitogenactivated protein kinase in the ferret lung cancer model. Carcinogenesis 2006;27:1410-9.
Matsuzaki T. Immunomodulation by trestment with Lactobacillus casei strain shirota. Int J Food Microbio! 1998:41(2):133-40
Salminen S, Isolauri E, Salminen E. Probiotics and stabilization of the gut mucosal barrier. Asia Pacific J Clin Nutr 1996:5(1):53-6.
Okawa T, Niibe H. Arai T. et al. Effect of LC 9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase Ill, multicenter, randomized. controlled study. Cancer 1993:72(6):1949-54.
Barnett M. Overview of complementary therapies in cancer care. IN: Textbook of Integrated Cancer Care. Holistic, complementary. and Creative approaches. Barraclough J, ed. NewYork: Oxford University Press 2001:1-17.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
